Fig. 4.

Early treatment with KML29 and celecoxib combination prevents MIA-induced secondary allodynia. Early treatment with combination of KML29 and CXB, given on days 1–3 post-MIA induction, significantly improve the hindpaw withdrawal threshold over the 14-day development of the model (P < 0.0001; two-way ANOVA with Tukey post hoc test; ^$P < 0.05, ****P < 0.0001, **P < 0.01, *P < 0.05, ^###P < 0.001, ^##P < 0.01, ^#P < 0.05, ^∇∇∇P < 0.001, ^∇P < 0.05; n = 8–10), compared to either treatment alone or vehicle. Data are mean values ± SEM. ANOVA, analysis of variance; BL, baseline; CXB, celecoxib; MIA, sodium monoiodoacetate; VEH, vehicle; *post hoc comparison between KML29 + CXB and vehicle; ^#post hoc comparison between KML29 and KML29 + CXB; ^$post hoc comparison between CXB and vehicle; ^∇post hoc comparison between CXB and KML29 + CXB